Understanding the Voting Rights of Ipsen's Share Capital

Author: Dylan Bailey Updated: 05-12-2025 12:16 PM

Overview of Ipsen's Share Capital and Voting Rights

In the world of finance, understanding the dynamics of voting rights and shares can heavily influence investment decisions. For Ipsen, a prominent name in biopharmaceutical innovation, details about their voting rights and share capital are a focal point for shareholders and interested parties.

Importance of Voting Rights

Voting rights are essential for shareholders as they influence corporate decisions, including board elections and corporate policies. For Ipsen, the voting rights associated with their shares are outlined clearly for transparency and regulatory compliance, ensuring that shareholders are informed of their power and stake within the company.

Share Capital Composition

As of April 30, 2025, Ipsen's total number of shares composing the share capital reached an impressive 83,814,526. This figure plays a crucial role in calculating total voting rights, which stands significantly at 131,926,335 gross voting rights. This includes shares that provide double voting rights as well as treasury shares.

Understanding Gross and Net Voting Rights

The gross total of 131,926,335 voting rights includes all shares with voting privileges. On the other hand, the net total of 130,817,797 voting rights reflects the actual influence shareholders have when excluding shares without voting rights. This distinction is vital for investors looking to understand their real impact.

Regulatory Compliance

Ipsen is required to adhere to specific regulations under the French Commercial Code and the General Regulation of the Autorité des Marchés Financiers. These regulations ensure that shareholders are kept informed about their voting capacities and any changes that may occur.

The Market Presence of Ipsen

Ipsen's shares are traded on Euronext Paris, recognized by their ISIN code FR 0010259150. This listing underlines their presence in the biopharmaceutical sector, contributing significantly to investments related to health care advancements.

The Importance of Transparency

Transparency in corporate governance can increase investor confidence, and Ipsen's regular updates regarding their share capital and voting rights are a testament to this commitment. Providing monthly updates enables stakeholders to make informed decisions regarding their investments.

Frequent Updates

Staying updated with the latest information regarding voting rights is vital for institutional and individual investors alike. Ipsen consistently provides details to ensure that all shareholders are aware of their rights and the company's standing.

Frequently Asked Questions

What are voting rights?

Voting rights are privileges that allow shareholders to vote on important company decisions, influencing the direction and governance of the company.

How does Ipsen ensure transparency in their share capital?

Ipsen regularly publishes updates on the number of shares and voting rights to keep shareholders informed and engaged.

What is the significance of gross vs. net voting rights?

Gross voting rights include all shares with voting privileges, while net voting rights exclude shares that do not contribute to voting, providing a clearer view of shareholder influence.

Where is Ipsen's stock traded?

Ipsen's stock is traded on Euronext Paris, making it accessible to a wide range of investors interested in biopharmaceuticals.

What is Ipsen's current total number of voting rights?

As of the latest report, Ipsen has a total of 131,926,335 gross voting rights and 130,817,797 net voting rights.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.